Key Insights• According to the research report, "Mexico EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Mexico EPA & DHA Market is expected to reach a market size of more than USD 64.52 Million by 2031. The Mexican EPA & DHA market is steadily expanding as the country faces one of the highest burdens of cardiometabolic disease in the Americas, driven by high rates of obesity and diabetes, an accelerating demographic transition, and growing consumer awareness of preventive nutrition. According to INEGI's Encuesta Intercensal 2025, Mexico's population reached approximately 130.4 million, with 19,204,670 people aged 60 and older, representing 14.7% of the population, a level the government had not expected to reach until 2030. Preliminary INEGI data show that Mexico registered 818,437 deaths in 2024, up 2.3% from the previous year, with heart disease ranking as the leading cause of death at 192,563 deaths, followed by diabetes mellitus at 112,641 deaths. The growing clinical burden is placing additional pressure on Mexico's public health system and consumer health sector to strengthen access to EPA and DHA through dietary supplements, prescription therapies, fortified foods, and infant nutrition.• Mexico's EPA & DHA market is characterized by a mixed ecosystem comprising multinational consumer health companies, direct-selling organizations, domestic pharmaceutical laboratories, pharmacy chains, and a growing pet food industry. Pharmacy chains such as Farmacias Guadalajara, Farmacias del Ahorro, and Farmacias San Pablo, alongside Walmart de México, Costco, and e-commerce platforms such as Mercado Libre and Amazon México, function as the primary distribution channels for omega-3 supplements. Direct-selling companies, including Amway (Nutrilite), Herbalife, and Omnilife, also play a significant role in reaching consumers outside major urban centers.

According to data published by the National Association of the Supplement Industry (ANAISA) in May 2024, Mexico's dietary supplement segment grew 7.3% to sales of approximately MXN 59 billion, with around 15 million people consuming dietary supplements. In January 2025, Nestlé announced an investment of USD 1 billion in Mexico for 2025–2027, covering its plants in Veracruz, Guanajuato, Querétaro, and the State of Mexico.• Regulatory oversight for EPA and DHA products is administered by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) under the General Health Law and the Reglamento de Control Sanitario de Productos y Servicios. Omega-3 products are generally marketed as suplementos alimenticios (food supplements), which do not require pre-market registration but must comply with labelling, hygiene, and advertising rules, while prescription omega-3 products require sanitary registration as medicines. Packaged foods and non-alcoholic beverages are subject to the NOM-051 front-of-pack warning label system, whose third and strictest phase took effect in October 2025. The Mexican EPA & DHA market is largely supplied through imported refined oils and finished products, with GOED's 2026 Ingredient Market Report identifying Mexico as one of the key emerging growth opportunities for omega-3 ingredients globally.Market Outlook• A defining characteristic of Mexico's EPA & DHA market is the progressive formalization and professionalization of the food supplement sector. Industry associations such as ANAISA are promoting responsible labelling and compliance with the Reglamento de Control Sanitario de Productos y Servicios and NOM-251-SSA1-2012 hygiene practices, while COFEPRIS continues to issue public alerts against misleading supplement products that claim to cure or reverse chronic disease.

This is encouraging consolidation toward established multinational and domestic brands with quality certifications, clear dosing, and evidence-based positioning. Simultaneously, omega-3 products are increasingly positioned around cardiovascular health, triglyceride management, cognitive function, and joint health, supported by pharmacist recommendations and physician guidance in private clinics, including the consultorios adjacent to pharmacies (CAFs) that serve millions of Mexicans each year.• The market also reflects Mexico's growing emphasis on nutrition policy and chronic disease prevention. The Mexican government's ban on the sale of ultra-processed foods and sugary drinks in schools, which took effect on March 29, 2025, and the NOM-051 front-of-pack warning label system are reshaping the food and beverage landscape and encouraging manufacturers to reformulate products with healthier nutrient profiles, creating opportunities for omega-3-fortified dairy, eggs, and functional foods that avoid excess warning seals. In infant nutrition, INEGI reported approximately 1,672,227 registered births in 2024, with the birth rate falling from 52.2 to 47.7 births per 1,000 women aged 15 to 49, which is constraining formula volumes but encouraging manufacturers to compete on premium DHA- and ARA-fortified formulations.Market DynamicsDriver: Rising cardiometabolic disease burden supported by demographic and epidemiological transitionMexico's EPA & DHA market is primarily driven by the high prevalence of cardiovascular and metabolic conditions associated with obesity, diabetes, and demographic aging. Heart disease was the leading cause of death in Mexico in 2024, accounting for 192,563 deaths, while diabetes mellitus ranked second at 112,641 deaths, according to preliminary INEGI data. The rapid aging of the population, with 19.2 million people aged 60 and older in 2025, is reinforcing demand for products that support cardiovascular, cognitive, and joint health.

Elevated triglycerides and dyslipidemia are highly prevalent among Mexican adults, supporting physician and pharmacist recommendation of omega-3 supplementation and prescription omega-3 therapies. As public health programs and private healthcare providers continue promoting earlier diagnosis and management of cardiometabolic risk, pharmacies and retailers are witnessing growing demand for EPA and DHA products with clear health positioning.Challenge: Regulatory ambiguity, misleading product claims, and dependence on imported ingredientsOne of the principal challenges facing Mexico's EPA & DHA market is the uneven quality of products in the food supplement category and the country's dependence on imported refined oils. Because food supplements do not require pre-market registration, the market includes products with inconsistent EPA and DHA content, oxidation levels, and labelling quality, and COFEPRIS has repeatedly issued alerts against misleading supplements that pose risks to consumer health. The distinction between food supplements, herbal remedies, and medicines can be ambiguous, complicating market entry for new omega-3 formats. Additionally, Mexico relies heavily on imported refined fish oil and finished softgels, exposing brands to raw material volatility and currency fluctuations. Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% below 2025, following a coastal El Niño event, which is expected to tighten global fish oil supply.

Price sensitivity among lower-income consumers and the large informal retail sector also limit penetration of premium high-concentration and algal omega-3 products.Trend: Growth of e-commerce, private label, and premium pet nutritionMexico is experiencing a significant shift in omega-3 distribution and consumption supported by the rapid growth of e-commerce, warehouse clubs, and pharmacy private labels. Online marketplaces such as Mercado Libre and Amazon México are expanding consumer access to imported omega-3 brands, krill oil, and algal DHA products, while pharmacy chains and Costco are building private-label omega-3 ranges that bring high-quality products to more price-sensitive consumers. Simultaneously, the pet nutrition sector is emerging as a significant demand pocket. Mexico's pet food market was projected at approximately USD 3.29 billion in 2024 and is expected to grow to around USD 4.58 billion by 2029, with dogs accounting for 69.8% of the companion animal population and cat ownership rising rapidly. Premium pet foods and supplements increasingly incorporate fish oil for skin, coat, and joint health. The growing emphasis on healthier eating, driven by front-of-pack labelling and school food regulations, is also expected to support the development of omega-3-fortified foods.Policies• COFEPRIS Food Supplement Framework: Omega-3 products containing EPA and DHA are generally regulated as suplementos alimenticios under the Reglamento de Control Sanitario de Productos y Servicios.

Food supplements must not claim to prevent, treat, or cure disease, must comply with labelling requirements including the legend stating that the product is not a medicine, and must be manufactured in accordance with NOM-251-SSA1-2012 hygiene practices. Imported products must comply with sanitary import requirements.• Sanitary Registration of Medicines: Prescription omega-3 products, including omega-3-acid ethyl esters indicated for hypertriglyceridemia, require sanitary registration from COFEPRIS as medicines under the General Health Law and the Reglamento de Insumos para la Salud, including evidence of quality, safety, and efficacy and compliance with good manufacturing practices.• NOM-051 Front-of-Pack Warning Labels: Packaged foods and non-alcoholic beverages must display warning seals for excess calories, sugars, saturated fats, trans fats, and sodium under NOM-051-SCFI/SSA1-2010. The third phase, which took effect in October 2025, applies stricter nutrient thresholds, influencing the formulation and positioning of omega-3-fortified foods and beverages.• School Food Regulations: The national guidelines prohibiting the sale of ultra-processed foods and sugary drinks in schools, which took effect on March 29, 2025, are encouraging food manufacturers to develop healthier products for children, creating opportunities for nutrient-enhanced formulations, including those fortified with DHA.• Advertising Control and Market Surveillance: COFEPRIS regulates the advertising of food supplements under the Reglamento de la Ley General de Salud en Materia de Publicidad and conducts market surveillance, including public alerts against products making misleading or unauthorized therapeutic claims, strengthening consumer protection and supporting the positioning of compliant omega-3 brands.Segment AnalysisMexico EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Mexico, particularly in infant formula, growing-up milks, prenatal supplements, and children's nutrition products. DHA is widely added to infant formulas marketed in Mexico by multinational manufacturers, and prenatal vitamins with DHA are commonly recommended by obstetricians in private practice.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Mexico, driven by increasing physician recommendation of high-EPA concentrates and prescription omega-3 therapies for triglyceride management and cardiovascular risk reduction in a population with high rates of dyslipidemia and diabetes.Mexico EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Mexico due to its cost-effectiveness and broad consumer familiarity. Fish oil products are primarily imported from Peru, Chile, the U.S., and Europe, while domestic sardine and anchovy fisheries in the Gulf of California and Pacific coast supply fishmeal and fish oil mainly for aquaculture and animal feed.• Algae Oil maintains a growing position within Mexico, particularly in infant formula, vegetarian supplements, and children's products, supplied primarily by multinational algal oil producers.• Krill Oil is a premium source category available mainly through pharmacies, health food stores, and e-commerce platforms, positioned for absorption and smaller capsule sizes among higher-income consumers.• Other Marine Sources hold a niche position in the Mexican market, including cod liver oil, salmon oil, and shark liver oil, primarily used in traditional liquid supplements and pet nutrition.Mexico EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Mexico, supported by a supplement sector with sales of approximately MXN 59 billion and around 15 million consumers, according to ANAISA data published in May 2024. Omega-3 supplements are sold through pharmacies, supermarkets, warehouse clubs, direct selling, and e-commerce.• Pharmaceuticals represent an important application segment, driven by prescription omega-3-acid ethyl esters for hypertriglyceridemia distributed through private pharmacies and, to a lesser extent, public health institutions such as IMSS and ISSSTE.• Infant Formula represents a strategically important application segment, with DHA and ARA widely included in infant formulas and growing-up milks.

Approximately 1.67 million births were registered in 2024, sustaining sizeable formula demand despite a declining birth rate.• Food & Beverages encompasses omega-3-enriched eggs, milk, yogurts, and functional beverages. The NOM-051 front-of-pack labelling system and school food regulations are encouraging reformulation toward healthier products.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in public and private hospitals for critically ill, surgical, and oncology patients.• Pet Nutrition represents the fastest-growing application segment in Mexico, supported by rising pet ownership and premiumization. Mexico's pet food market was projected at approximately USD 3.29 billion in 2024, with cat food expected to grow at around 7.2% CAGR from 2024 to 2029.Major EPA & DHA Manufacturers Operating in Mexico• Nestlé, Abbott, Reckitt (Mead Johnson), Bayer, Amway (Nutrilite), Herbalife, GNC, Genomma Lab, dsm-firmenich, KD Pharma Group, and Aker BioMarine are leading players in the Mexican EPA & DHA market, offering finished supplements, DHA-fortified infant formula, refined fish oil ingredients, algal oils, and krill oil. In January 2025, Nestlé announced a USD 1 billion investment in its Mexican operations for 2025–2027. Their strong presence, broad distribution networks, scientific support programs, and established relationships with pharmacies, physicians, and retailers have driven adoption across the Mexican market.• The market is also supported by domestic laboratories, contract manufacturers, private-label suppliers, and ingredient distributors that provide formulation, encapsulation, and import support. With strong consumer demand, expanding modern retail, and its position as a gateway to Latin America, Mexico remains one of the most promising emerging omega-3 markets.Mexico EPA & DHA Supply and Pricing Economics• EPA and DHA products in Mexico represent value-added nutritional products whose pricing depends on source, concentration, brand positioning, and distribution channel.

Pricing varies considerably between mass-market fish oil softgels, high-concentration products, krill oil, and algal oil.• Retail pricing is influenced by imported raw material costs, peso-dollar exchange rate movements, and import logistics. Refined fish oil prices normalized by late 2024 after the El Niño-related disruption, but the reduced 2026 Peruvian quota is expected to place renewed upward pressure on raw material costs.• Prescription omega-3 products are paid largely out-of-pocket through private pharmacies, as public institutions prioritize lower-cost lipid-lowering medicines. Private health insurance coverage remains limited, making price a key purchasing factor.• Direct-selling and pharmacy private labels offer lower-cost entry points, while premium international brands are sold through specialty stores, Costco, and e-commerce, targeting higher-income urban consumers.Market Outlook by Consumer Health Spending and Supply Infrastructure• Mexico's EPA & DHA market growth is strongly linked to consumer health spending, the rising cardiometabolic disease burden, and the expansion of modern retail and e-commerce, although price sensitivity and regulatory ambiguity remain significant factors influencing adoption.• Private consumer spending drives the supplement segment, with pharmacies, warehouse clubs, and direct selling functioning as key channels. Private-label omega-3 ranges and online marketplaces are expanding access to more price-sensitive consumers.• The future growth opportunity for EPA and DHA in Mexico depends on improving product quality standards, strengthening consumer education on omega-3 benefits, expanding physician and pharmacist recommendations, and developing omega-3-fortified foods that comply with NOM-051 labelling requirements. Greater integration of e-commerce, pet nutrition, and premium infant formula, combined with Mexico's recognition by GOED as a key emerging opportunity, will likely support sustained long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.